Septerna, Inc.
Septerna develops oral small molecule GPCR modulators for endocrinology, immunology, inflammation, and metabolic diseases using its Native Complex Platform.
10-KSep 24Latest SEC filing, period to Jun 30
Aug 25Latest story
Sign inSign inSepterna develops oral small molecule GPCR modulators for endocrinology, immunology, inflammation, and metabolic diseases using its Native Complex Platform.